PDF(Pubmed)
Abstract：
Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
摘要：
间质性肺病(ILD)是许多全身性自身免疫性风湿性疾病(SARD)的重要并发症,虽然临床表现，个人之间的严重程度和前景可能差异很大。尽管流行,没有解决筛查问题的具体指导方针，在这一不同群体中ILD的诊断和管理。预计ACR和EULAR的指导方针，但是需要针对英国的指导方针来考虑英国国民健康服务的框架，本地许可和资金策略。本文概述了指南工作组制定的英国风湿病学会SARD-ILD诊断和管理指南的预期范围。它特别确定了要考虑的SARD，以及将进行系统审查的总体原则。专家共识将基于最新的现有证据，以纳入最终指南。需要解决的关键问题包括筛查ILD的建议，确定监测和药理学和非药理学管理的方法和频率。该指南将根据《创建临床指南：英国风湿病学会方案5.1版》中概述的方法和过程制定。
